Company Profile
Oric Pharmaceuticals, Inc. Stock Price, News & Analysis
- Ticker:
- ORIC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
12.93 USD (0.00%)
Close
Last updated: August 6, 2026
789M USD
Market cap
Why the stock is moving
The latest monitored company update is “ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
Company overview
Oncology Resistance Biology
ORIC Pharmaceuticals develops therapies intended to overcome mechanisms of treatment resistance in cancer. Its programs target epigenetic and signaling pathways that allow tumors to adapt to standard treatments.
Rinzimetostat
Rinzimetostat is an allosteric EED inhibitor that suppresses PRC2 activity. It is being developed with the androgen-receptor inhibitor darolutamide for metastatic castration-resistant prostate cancer after prior abiraterone treatment.
Himalayas-1
Himalayas-1 is the planned global Phase 3 registrational trial of rinzimetostat plus darolutamide in post-abiraterone metastatic castration-resistant prostate cancer. Dose-optimization results supported selection of 400 mg once daily as the recommended Phase 3 dose.
Enozertinib
Enozertinib is another clinical-stage ORIC oncology program approaching multiple data updates. The company intends to use these results to determine whether the asset is ready to enter registrational development.
Future catalysts
Initiation of the Phase 3 Himalayas-1 trial expected in the first half of 2026.
Multiple enozertinib clinical updates expected in the second half of 2026 ahead of a potential registrational trial.
Recent news
- 01
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Source: Oric Pharmaceuticals, Inc.
- 02
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
Source: Oric Pharmaceuticals, Inc.
- 03
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
Source: Oric Pharmaceuticals, Inc.
- 04
- 05
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Source: Oric Pharmaceuticals, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Oric Pharmaceuticals, Inc. (ORIC)?
Oric Pharmaceuticals, Inc. (ORIC) most recently closed at 12.93 USD, a 0.00% move versus the previous session.
What is the market cap of Oric Pharmaceuticals, Inc. (ORIC)?
Oric Pharmaceuticals, Inc. currently has a market capitalization of 789M USD on BioPharmSignal.
What does Oric Pharmaceuticals, Inc. do?
Oncology Resistance Biology ORIC Pharmaceuticals develops therapies intended to overcome mechanisms of treatment resistance in cancer. Its programs target epigenetic and signaling pathways that allow tumors to adapt to standard treatments. Rinzimetostat Rinzimetostat is an allosteric EED inhibitor that suppresses PRC2 activity. It is being developed with...
On which exchange is ORIC stock listed?
Oric Pharmaceuticals, Inc. (ORIC) is associated with NASDAQ, United States, Biopharma.
What is rinzimetostat?
Rinzimetostat Rinzimetostat is an allosteric EED inhibitor that suppresses PRC2 activity.
Which conditions is Oric Pharmaceuticals, Inc. targeting with rinzimetostat?
Oric Pharmaceuticals, Inc. is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Oric Pharmaceuticals, Inc. describe recent progress with rinzimetostat?
Initiation of the Phase 3 Himalayas-1 trial expected in the first half of 2026. Multiple enozertinib clinical updates expected in the second half of 2026 ahead of a potential registrational trial.
What is enozertinib?
Enozertinib Enozertinib is another clinical-stage ORIC oncology program approaching multiple data updates.